PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

被引：1
|
作者：
Addeo, Alfredo [1 ]
Banna, Giuseppe Luigi [2 ]
机构：
[1] Univ Hosp Geneva, Oncol Dept, CH-1205 Geneva, Switzerland
[2] Cannizzaro Hosp, Div Med Oncol, Catania, Italy
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
PD-L1; EXPRESSION; ATEZOLIZUMAB; NIVOLUMAB; DOCETAXEL; BLOCKADE; TRIAL; NSCLC;
D O I：
10.21037/tlcr.2018.07.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S283 / S286
页数：4
相关论文
共 50 条
  • [31] When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Laurent Mhanna
    Nicolas Guibert
    Julie Milia
    Julien Mazieres
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [32] When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Mhanna, Laurent
    Guibert, Nicolas
    Milia, Julie
    Mazieres, Julien
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (07)
  • [33] Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
    Guo, Xiaojin
    Du, He
    Li, Jiayu
    Yang, Menghang
    Xiong, Anweng
    Zhang, Haiping
    Wu, Fengying
    [J]. CANCER DRUG RESISTANCE, 2022, 5 (01) : 15 - 24
  • [34] USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer
    Fraile, Julia M.
    Manchado, Eusebio
    Lujambio, Amaia
    Quesada, Victor
    Campos-Iglesias, Diana
    Webb, Thomas R.
    Lowe, Scott W.
    Lopez-Otin, Carlos
    Freije, Jose M. P.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (10) : 4164 - 4175
  • [35] Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
    Campo, Meghan
    Al-Halabi, Hani
    Khandekar, Melin
    Shaw, Alice T.
    Sequist, Lecia V.
    Willers, Henning
    [J]. ONCOLOGIST, 2016, 21 (08): : 964 - 973
  • [36] Sequencing therapies in oncogene-driven non-small-cell lung cancer: how to get the best mileage?
    Sukrithan, Vineeth
    Snyder, Rose
    Cheng, Haiying
    Halmos, Balazs
    [J]. FUTURE ONCOLOGY, 2019, 15 (25) : 2899 - 2904
  • [37] The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art
    Franceschini, D.
    De Rose, F.
    Cozzi, S.
    Franzese, C.
    Rossi, S.
    Finocchiaro, G.
    Toschi, L.
    Santoro, A.
    Scorsetti, M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
  • [38] Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer
    Lui, Mei-Sze Macy
    Chiang, Ka-Yan
    Ho, Chung-Man James
    Tam, Chi-Chun Terence
    Lam, Chi-Leung
    Lee, Yun-Chor Gary
    Ip, Sau-Man Mary
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [39] TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC
    Benouaich-Amiel, Alexandra
    Gal, Omer
    Dudnik, Elizabeth
    Rotem, Ofer
    Finket, Inbar
    Peretz, Idit
    Zer, Alona
    Mandel, Jacob
    Siegal, Tali
    Bar, Jair
    Yust-Katz, Shlomit
    [J]. NEURO-ONCOLOGY, 2020, 22 : 1 - 1
  • [40] Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer
    Burns, Timothy F.
    Dobromilskaya, Irina
    Murphy, Sara C.
    Gajula, Rajendra P.
    Thiyagarajan, Saravanan
    Chatley, Sarah N. H.
    Aziz, Khaled
    Cho, Yoon-Jae
    Tran, Phuoc T.
    Rudin, Charles M.
    [J]. MOLECULAR CANCER RESEARCH, 2013, 11 (04) : 329 - 338
12345